MiniMed Group (NASDAQ:MMED) Price Target Raised to $26.00 at Mizuho

MiniMed Group (NASDAQ:MMED) had its price target lifted by research analysts at Mizuho from $21.00 to $26.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s price objective indicates a potential upside of 15.97% from the stock’s current price.

Several other analysts have also recently weighed in on the company. Weiss Ratings raised MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. UBS Group began coverage on shares of MiniMed Group in a research report on Tuesday, July 28th. They issued a “buy” rating and a $25.00 target price for the company. BTIG Research raised their price target on shares of MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday. Bank of America increased their target price on shares of MiniMed Group from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company lowered their target price on shares of MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.85.

MiniMed Group Price Performance

Shares of MMED opened at $22.42 on Wednesday. The company has a market capitalization of $6.31 billion and a price-to-earnings ratio of -32.97. The company has a 50-day moving average of $17.65. MiniMed Group has a fifty-two week low of $10.65 and a fifty-two week high of $22.74.

MiniMed Group (NASDAQ:MMED) last released its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The business had revenue of $837.00 million for the quarter. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. As a group, sell-side analysts expect that MiniMed Group will post 0.66 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of MiniMed Group by 7,527.5% in the 2nd quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock valued at $29,848,000 after purchasing an additional 1,970,314 shares during the last quarter. J. Goldman & Co LP acquired a new stake in MiniMed Group in the second quarter valued at about $12,412,000. Readystate Asset Management LP bought a new position in MiniMed Group in the second quarter valued at about $4,400,000. Bank of America Corp DE raised its stake in MiniMed Group by 377.0% during the second quarter. Bank of America Corp DE now owns 238,819 shares of the company’s stock worth $3,570,000 after acquiring an additional 188,756 shares in the last quarter. Finally, Freestone Grove Partners LP bought a new position in shares of MiniMed Group in the second quarter worth about $1,745,000.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 net sales of $843 million, up 17% year over year, with organic U.S. sales growth accelerating to 13% and international sales rising 18% as reported. Earnings per share also exceeded analyst expectations. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Management raised its fiscal 2027 organic revenue-growth guidance, signaling confidence that recent momentum can continue. The company also said its product pipeline is progressing ahead of schedule, including FDA submission plans for MiniMed Fit™, CE Mark progress for MiniMed Flex™, completion of enrollment in the Vivera™ FCL U.S. pivotal trial, and IDE approval for a next-generation extended-wear sensor. MiniMed Group Releases Q1 2027 Financial Results
• Positive Sentiment: BTIG Research raised its price target to $28 from $25 and maintained a “buy” rating, reflecting expectations for further upside based on the company’s growth outlook. MiniMed Group Price Target Increase
• Neutral Sentiment: The earnings call highlighted the quarter’s performance and pipeline developments, giving investors additional detail on the company’s operating outlook. MiniMed Group Q1 2027 Earnings Call Transcript
• Negative Sentiment: The consensus broker price target is $21.62, below the stock’s recent quoted level, suggesting that some analysts see limited near-term upside despite the improved operating results. MiniMed Group Receives Consensus Target Price

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.